Nordmark Arzneimittel Gmbh & Co. Kg

Other

Nordmark Arzeimittel Gmbh and Co, Kg

Nordmark Areneimittel Gmbh & Co. Kg

Manfred Kurfürst

Thomas Moest

Christian Rämsch

Olaf Friedrich

Thomas Schräder

Walter Doleschal

Stefan Schmidbauer

Thierry Berney

Daniel Brandhorst

Heide Brandhorst

Christian Raemsch

Nicole Raemsch-Guenther

Silke Huettler

Pascal Bucher

Rainer Friedel

Silke Hüttler

Nicole Raemsch-Guenter

The pharmaceutical preparation for the treatment of pancreatic insufficiency comprises a liquid administering form of enzymes.

Pharmaceutical preparation

The invention is a method for reducing the viral and microbial content of biological extracts which contain solids. The method comprises the steps of, (1), providing a biological extract which contains solids that comprise a biologically active substance, selected from enzymes, proteins and peptides, or a mixture of such substances; and (2) subjecting the biological extract to a high-pressure treatment; wherein the biological activity of the biological extract after the high-pressure treatment is at least 50% of the biological activity of the biological extract before the high-pressure treatment.

Method for reducing the viral and microbial load of biological extracts containing solids

In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.

Pancreatine pellets and method of producing same

In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight.

Method for producing pancreatin pellets

The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.

Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof

The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84&#xb0; C., preferably 80&#xb0; C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 login comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Pancreatin and method for reducing the viral and microbial contamination of pancreatin

The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of It is provided for that the enzymes of the excess fermentation are separated by a multistage chromatography method by exclusively using chromatography materials on styrene/divinyl-benzene base and/or on base of in particular ceramic hydroxylapatite.

Method for purifying enzymes from clostridium histolyticum using multi-stage chromatography

Growing community of inventors

Moorrege, Germany

Manfred Kurfürst